• Marcello Migliore, Damiano Calvo, Alessandra Criscione, Cristina Viola, Giuseppe Privitera, Corrado Spatola, Hector Soto Parra, Stefano Palmucci, Nicola Ciancio, Rosario Caltabiano, and Giuseppe Di Maria.
• Academic Thoracic Surgery Unit, A.O.U. Policlinico-Vittorio Emanuele, Department of Surgery, University of Catania, Catania, Italy.
• Future Oncol. 2015 Jan 1; 11 (2 Suppl): 47-52.

AbstractCytoreductive surgery and hyperthermic-intraoperative-intrapleural-chemotherapy (HITHOC) is a known approach for malignant pleural diseases (MPD). This study was started to clarify the role of cytoreductive surgery and HITHOC in MPD. Criteria of inclusion were early-stage disease in malignant pleural mesothelioma (MPM), young age, good condition and selected stage-M1a lung cancer. Six patients with MPM and two patients with lung cancer were enrolled. After surgical debulking, intrapleural cisplatin was administered for 60 min at 42.5°C. Wedge, rib resection and repaired diaphragm were added in three, one and one patient, respectively. Morbidity, toxicity and mortality was nil. Hospital stay was 8 days. Mean survival is 13.6 months. This experience confirms that cytoreductive surgery and HITHOC is a good option in the treatment of MPD. A randomized controlled trial is necessary.

44 keywords...

hide…